AbbVie 4: Quaggin Susan E bought 59 shares at $261.59 on 2026-09-30 (Oct 2, 2026)

=== SEC Form 4 — Statement of Changes in Beneficial Ownership === Document Type: 4 Period of Report: 2026-09-30 10b5-1 Pre-arranged Plan: No --- Issuer --- Name: AbbVie Inc. (ABBV) CIK: 0001551152 --- Reporting Owner --- Name: Quaggin Susan E CIK: 0001997505 Role: Director --- Derivative Transactions --- [Transaction #1] Security: Stock Equivalent Units Date: 2026-09-30 | Code: A (Grant or award) Shares: +59 | Price: $261.59 Exercise Price: $261.59 Shares Owned After: 918 | Ownership: D (Direct) Footnotes: [F1] Director fees credited to an unfunded book account in the director's name are distributed over a period equal to the director's years of board service, generally commencing at the later of age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock. [F1] Director fees credited to an unfunded book account in the director's name are distributed over a period equal to the director's years of board service, generally commencing at the later of age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock. [F2] Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. --- Footnotes (Complete Index) --- F1: Director fees credited to an unfunded book account in the director's name are distributed over a period equal to the director's years of board service, generally commencing at the later of age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock. F2: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. --- Signature --- /s/ /s/ T.O. Odutayo, Attorney-in-Fact for Susan E. Quaggin (2026-10-02)